New England Journal of Medicine
February 22, 2018 Vol. 378 No. 8
Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth
Julie E. Bines, M.D., Jarir At Thobari, Ph.D., Cahya Dewi Satria, M.D., Amanda Handley, M.P.H.,
Emma Watts, B.Sci., Daniel Cowley, Ph.D., Hera Nirwati, M.D., Ph.D., James Ackland, B.Sci.,
Jane Standish, M.B., B.S., Frances Justice, B.Sci., Gabrielle Byars, M.Bio.Med.Sci., Katherine J. Lee, Ph.D., Graeme L. Barnes, M.D., Novilia S. Bachtiar, Dr.M.Kes., Ajeng Viska Icanervilia, .D.,
Karen Boniface, B.Sci., Nada Bogdanovic-Sakran, B.Sci., Daniel Pavlic, B.Sci., Ruth F. Bishop, A.O., D.Sc., Carl D. Kirkwood, Ph.D., Jim P. Buttery, M.D., and Yati Soenarto, M.D., Ph.D.
RV3-BB was efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule in Indonesia. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612001282875.)